{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:43Z","timestamp":1792788643108,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273315"],"award-info":[{"award-number":["82273315"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZC20231824"],"award-info":[{"award-number":["GZC20231824"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,3,17]]},"DOI":"10.1038\/s41388-026-03693-0","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:36:14Z","timestamp":1771320974000},"page":"889-904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tumor cell-intrinsic PD-1 in malignant ascites drives ovarian cancer progression via MAPK\/ERK signaling"],"prefix":"10.1038","volume":"45","author":[{"given":"Jia","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusha","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-0651","authenticated-orcid":false,"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushuang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5094-1376","authenticated-orcid":false,"given":"Hongxin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"3693_CR1","first-page":"937","volume":"93","author":"CA Doubeni","year":"2016","unstructured":"Doubeni CA, Doubeni AR, Myers AE. Diagnosis and management of ovarian cancer. Am Fam Phys. 2016;93:937\u201344.","journal-title":"Am Fam Phys"},{"key":"3693_CR2","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","volume":"393","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240\u201353.","journal-title":"Lancet"},{"key":"3693_CR3","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.7150\/thno.26345","volume":"8","author":"G Di Lorenzo","year":"2018","unstructured":"Di Lorenzo G, Ricci G, Severini GM, Romano F, Biffi S. Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives. Theranostics. 2018;8:4279\u201394.","journal-title":"Theranostics"},{"key":"3693_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bpobgyn.2016.12.001","volume":"41","author":"T Grunewald","year":"2017","unstructured":"Grunewald T, Ledermann JA. Targeted therapies for ovarian cancer. Best Pr Res Cl Ob. 2017;41:139\u201352.","journal-title":"Best Pr Res Cl Ob"},{"key":"3693_CR5","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1111\/jcmm.14133","volume":"23","author":"X Jiang","year":"2019","unstructured":"Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms. J Cell Mol Med. 2019;23:2303\u201313.","journal-title":"J Cell Mol Med"},{"key":"3693_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.biocel.2017.09.002","volume":"92","author":"J Mikula-Pietrasik","year":"2017","unstructured":"Mikula-Pietrasik J, Uruski P, Szubert S, Szpurek D, Sajdak S, Tykarski A, et al. Malignant ascites determine the transmesothelial invasion of ovarian cancer cells. Int J Biochem Cell B. 2017;92:6\u201313.","journal-title":"Int J Biochem Cell B"},{"key":"3693_CR7","doi-asserted-by":"publisher","first-page":"4318","DOI":"10.3390\/cancers13174318","volume":"13","author":"BP Rickard","year":"2021","unstructured":"Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, et al. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers. 2021;13:4318.","journal-title":"Cancers"},{"key":"3693_CR8","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/cas.12987","volume":"107","author":"S Kim","year":"2016","unstructured":"Kim S, Kim B, Song YS. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016;107:1173\u20138.","journal-title":"Cancer Sci"},{"key":"3693_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 2013;13:273\u201382.","journal-title":"Nat Rev Cancer"},{"key":"3693_CR10","first-page":"75","volume":"410","author":"K Chamoto","year":"2017","unstructured":"Chamoto K, Al-Habsi M, Honjo T. Role of PD-1 in immunity and diseases. Curr Top Microbiol. 2017;410:75\u201397.","journal-title":"Curr Top Microbiol"},{"key":"3693_CR11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","volume":"44","author":"MK Callahan","year":"2016","unstructured":"Callahan MK, Postow MA, Wolchok JD. Targeting T cell co-receptors for cancer therapy. Immunity. 2016;44:1069\u201378.","journal-title":"Immunity"},{"key":"3693_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/eji.202048747","volume":"51","author":"ZN Willsmore","year":"2021","unstructured":"Willsmore ZN, Coumbe B, Crescioli S, Reci S, Gupta A, Harris RJ, et al. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021;51:544\u201356.","journal-title":"Eur J Immunol"},{"key":"3693_CR13","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.22.01599","volume":"41","author":"C Robert","year":"2023","unstructured":"Robert C, Carlino MS, McNeil C, Ribas A, Grob JJ, Schachter J, et al. Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol. 2023;41:3998\u20134003.","journal-title":"J Clin Oncol"},{"key":"3693_CR14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1158\/2326-6066.CIR-19-0744","volume":"8","author":"D Chen","year":"2020","unstructured":"Chen D, Barsoumian HB, Yang L, Younes AI, Verma V, Hu Y, et al. SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti-PD-1-resistant model of non-small cell lung cancer. Cancer Immunol Res. 2020;8:883\u201394.","journal-title":"Cancer Immunol Res"},{"key":"3693_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257\u201365.","journal-title":"Lancet Oncol"},{"key":"3693_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","volume":"22","author":"J Kuruvilla","year":"2021","unstructured":"Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22:512\u201324.","journal-title":"Lancet Oncol"},{"key":"3693_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","volume":"21","author":"E Ghisoni","year":"2024","unstructured":"Ghisoni E, Morotti M, Sarivalasis A, Grimm AJ, Kandalaft L, Laniti DD, et al. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach. Nat Rev Clin Oncol. 2024;21:801\u201317.","journal-title":"Nat Rev Clin Oncol"},{"key":"3693_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00818-7","volume":"13","author":"L Wang","year":"2025","unstructured":"Wang L, Zhang Q, Wang X, Dong Z, Liu S, Wang Q, et al. Therapeutic landscape of ovarian cancer: recent advances and emerging therapies. Biomark Res. 2025;13:103.","journal-title":"Biomark Res"},{"key":"3693_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593.","journal-title":"Science"},{"key":"3693_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.it.2024.12.006","volume":"46","author":"R Gupta","year":"2025","unstructured":"Gupta R, Kumar R, Penn CA, Wajapeyee N. Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments. Trends Immunol. 2025;46:166\u201381.","journal-title":"Trends Immunol"},{"key":"3693_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","volume":"229","author":"JL Riley","year":"2009","unstructured":"Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229:114\u201325.","journal-title":"Immunol Rev"},{"key":"3693_CR22","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162:1242\u201356.","journal-title":"Cell"},{"key":"3693_CR23","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.29360","volume":"66","author":"H Li","year":"2017","unstructured":"Li H, Li X, Liu S, Guo L, Zhang B, Zhang J, et al. Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology. 2017;66:1920\u201333.","journal-title":"Hepatology"},{"key":"3693_CR24","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1073\/pnas.1921445117","volume":"117","author":"X Wang","year":"2020","unstructured":"Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, et al. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. P Natl Acad Sci USA. 2020;117:6640\u201350.","journal-title":"P Natl Acad Sci USA"},{"key":"3693_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adi2012","volume":"10","author":"C Martins","year":"2024","unstructured":"Martins C, Rasbach E, Heppt MV, Singh P, Kulcsar Z, Holzgruber J, et al. Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling. Sci Adv. 2024;10:eadi2012.","journal-title":"Sci Adv"},{"key":"3693_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.canlet.2019.06.013","volume":"460","author":"N Pu","year":"2019","unstructured":"Pu N, Gao S, Yin H, Li JA, Wu W, Fang Y, et al. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61\/CTGF via the hippo pathway. Cancer Lett. 2019;460:42\u201353.","journal-title":"Cancer Lett"},{"key":"3693_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.767466","volume":"9","author":"MJ Kim","year":"2021","unstructured":"Kim MJ, Ha SJ. Differential role of PD-1 expressed by various immune and tumor cells in the tumor immune microenvironment: expression, function, therapeutic efficacy, and resistance to cancer immunotherapy. Front Cell Dev Biol. 2021;9:767466.","journal-title":"Front Cell Dev Biol"},{"key":"3693_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume":"1248","author":"L Ai","year":"2020","unstructured":"Ai L, Xu A, Xu J. Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond. Adv Exp Med Biol. 2020;1248:33\u201359.","journal-title":"Adv Exp Med Biol"},{"key":"3693_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s42003-020-0845-0","volume":"3","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Duke-Cohan JS, Chaudhri A, Aksoylar HI, Wang Q, Council A, et al. Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation. Commun Biol. 2020;3:128.","journal-title":"Commun Biol"},{"key":"3693_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/diagnostics12010189","volume":"12","author":"J Swiderska","year":"2022","unstructured":"Swiderska J, Kozlowski M, Nowak K, Rychlicka M, Branecka-Wozniak D, Kwiatkowski S, et al. Clinical relevance of soluble forms of immune checkpoint molecules sPD-1, sPD-L1, and sCTLA-4 in the diagnosis and prognosis of ovarian cancer. Diagnostics. 2022;12:189.","journal-title":"Diagnostics"},{"key":"3693_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.716747","volume":"15","author":"H Li","year":"2021","unstructured":"Li H, Zheng C, Han J, Zhu J, Liu S, Jin T. PD-1\/PD-L1 axis as a potential therapeutic target for multiple sclerosis: a T cell perspective. Front Cell Neurosci. 2021;15:716747.","journal-title":"Front Cell Neurosci"},{"key":"3693_CR32","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","volume":"1773","author":"JA McCubrey","year":"2007","unstructured":"McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, et al. Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263\u201384.","journal-title":"Biochim Biophys Acta"},{"key":"3693_CR33","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.bbrc.2018.03.007","volume":"498","author":"Z Wu","year":"2018","unstructured":"Wu Z, Wang T, Fang M, Huang W, Sun Z, Xiao J, et al. MFAP5 promotes tumor progression and bone metastasis by regulating ERK\/MMP signaling pathways in breast cancer. Biochem Biophys Res Co. 2018;498:495\u2013501.","journal-title":"Biochem Biophys Res Co"},{"key":"3693_CR34","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10555-012-9351-2","volume":"31","author":"KL Sodek","year":"2012","unstructured":"Sodek KL, Murphy KJ, Brown TJ, Ringuette MJ. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metast Rev. 2012;31:397\u2013414.","journal-title":"Cancer Metast Rev"},{"key":"3693_CR35","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","volume":"68","author":"K Sawada","year":"2008","unstructured":"Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008;68:2329\u201339.","journal-title":"Cancer Res"},{"key":"3693_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-3-319-91442-8_12","volume":"211","author":"H Andrlova","year":"2018","unstructured":"Andrlova H, Zeiser R, Meiss F. Cobimetinib (GDC-0973, XL518). Recent Results Cancer Res. 2018;211:177\u201386.","journal-title":"Recent Results Cancer Res"},{"key":"3693_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207\u201312.","journal-title":"Curr Opin Immunol"},{"key":"3693_CR38","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.3389\/fimmu.2018.01774","volume":"9","author":"H Yao","year":"2018","unstructured":"Yao H, Wang H, Li C, Fang JY, Xu J. Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Front Immunol. 2018;9:1774.","journal-title":"Front Immunol"},{"key":"3693_CR39","first-page":"58","volume":"1865","author":"Y Xia","year":"2016","unstructured":"Xia Y, Jeffrey ML, Young KH. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta. 2016;1865:58\u201371.","journal-title":"Biochim Biophys Acta"},{"key":"3693_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","volume":"85","author":"R Ullah","year":"2022","unstructured":"Ullah R, Yin Q, Snell AH, Wan L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol. 2022;85:123\u201354.","journal-title":"Semin Cancer Biol"},{"key":"3693_CR41","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.bbrc.2014.09.062","volume":"453","author":"T Li","year":"2014","unstructured":"Li T, Song T, Ni L, Yang G, Song X, Wu L, et al. The p-ERK-p-c-Jun-cyclinD1 pathway is involved in proliferation of smooth muscle cells after exposure to cigarette smoke extract. Biochem Biophys Res Co. 2014;453:316\u201320.","journal-title":"Biochem Biophys Res Co"},{"key":"3693_CR42","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1139\/bcb-2021-0513","volume":"100","author":"Z Liu","year":"2022","unstructured":"Liu Z, Xu Y, Liu X, Wang B. PCDH7 knockdown potentiates colon cancer cells to chemotherapy via inducing ferroptosis and changes in autophagy through restraining MEK1\/2\/ERK\/c-Fos axis. Biochem Cell Biol. 2022;100:445\u201357.","journal-title":"Biochem Cell Biol"},{"key":"3693_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109291","volume":"35","author":"AM Waters","year":"2021","unstructured":"Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, et al. Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep. 2021;35:109291.","journal-title":"Cell Rep"},{"key":"3693_CR44","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nrm2509","volume":"9","author":"R Anjum","year":"2008","unstructured":"Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9:747\u201358.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3693_CR45","first-page":"165","volume":"67","author":"X Li","year":"2020","unstructured":"Li X, Liu J, Sun H, Zou Y, Chen J, Chen Y, et al. SRPX2 promotes cell proliferation and invasion via activating FAK\/SRC\/ERK pathway in non-small cell lung cancer. Acta Biochim Pol. 2020;67:165\u201372.","journal-title":"Acta Biochim Pol"},{"key":"3693_CR46","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.omto.2021.11.008","volume":"23","author":"G Shi","year":"2021","unstructured":"Shi G, Shi P, Yu Y, Xu J, Ma J, Zhang Y, et al. Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment. Mol Ther-Oncolytics. 2021;23:488\u2013500.","journal-title":"Mol Ther-Oncolytics"},{"key":"3693_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47910-1","volume":"9","author":"LA De Sousa","year":"2019","unstructured":"De Sousa LA, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1\/PD-L1 signaling. Sci Rep-Uk. 2019;9:11472.","journal-title":"Sci Rep-Uk"},{"key":"3693_CR48","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1158\/1078-0432.CCR-16-1163","volume":"23","author":"AM Seifert","year":"2017","unstructured":"Seifert AM, Zeng S, Zhang JQ, Kim TS, Cohen NA, Beckman MJ, et al. PD-1\/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clin Cancer Res. 2017;23:454\u201365.","journal-title":"Clin Cancer Res"},{"key":"3693_CR49","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ccell.2021.04.004","volume":"39","author":"M Hornburg","year":"2021","unstructured":"Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S, et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 2021;39:928\u201344.","journal-title":"Cancer Cell"},{"key":"3693_CR50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12079-022-00698-8","volume":"17","author":"Z Geng","year":"2023","unstructured":"Geng Z, Pan X, Xu J, Jia X. Friend and foe: the regulation network of ascites components in ovarian cancer progression. J Cell Commun Signal. 2023;17:391\u2013407.","journal-title":"J Cell Commun Signal"},{"key":"3693_CR51","doi-asserted-by":"publisher","first-page":"10692","DOI":"10.3390\/ijms231810692","volume":"23","author":"DL Almeida-Nunes","year":"2022","unstructured":"Almeida-Nunes DL, Mendes-Frias A, Silvestre R, Dinis-Oliveira RJ, Ricardo S. Immune Tumor Microenvironment in Ovarian Cancer Ascites. Int J Mol Sci. 2022;23:10692.","journal-title":"Int J Mol Sci"},{"key":"3693_CR52","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","volume":"19","author":"K Abiko","year":"2013","unstructured":"Abiko K, Mandai M, Hamanishi J, Yoshioka Y, Matsumura N, Baba T, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res. 2013;19:1363\u201374.","journal-title":"Clin Cancer Res"},{"key":"3693_CR53","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13296","volume":"84","author":"B Santoso","year":"2020","unstructured":"Santoso B, Sa\u2019Adi A, Dwiningsih SR, Tunjungseto A, Widyanugraha M, Mufid AF, et al. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility. Am J Reprod Immunol. 2020;84:e13296.","journal-title":"Am J Reprod Immunol"},{"key":"3693_CR54","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/icb.2012.53","volume":"91","author":"M Mathieu","year":"2013","unstructured":"Mathieu M, Cotta-Grand N, Daudelin JF, Thebault P, Labrecque N. Notch signaling regulates PD-1 expression during CD8(+) T-cell activation. Immunol Cell Biol. 2013;91:82\u20138.","journal-title":"Immunol Cell Biol"},{"key":"3693_CR55","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.ccell.2018.02.005","volume":"33","author":"Y Liu","year":"2018","unstructured":"Liu Y, Liang X, Dong W, Fang Y, Lv J, Zhang T, et al. Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation. Cancer Cell. 2018;33:480\u201394.","journal-title":"Cancer Cell"},{"key":"3693_CR56","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ccell.2022.01.001","volume":"40","author":"S Kumagai","year":"2022","unstructured":"Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40:201\u201318.","journal-title":"Cancer Cell"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03693-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03693-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03693-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T23:02:56Z","timestamp":1771887776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03693-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,3,17]]}},"alternative-id":["3693"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03693-0","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All study participants provided informed consent. All procedures involving human participants were performed in accordance with relevant guidelines and regulations and were approved by the Research Ethics Committee of West China Hospital, Sichuan University (approval number: 2024-41), in accordance with the Declaration of Helsinki. All animal experiments were performed in accordance with relevant guidelines and regulations and were approved by the Institutional Animal Care and Use Ethics Committee of West China Hospital, Sichuan University (approval number: 20231215006).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}